Syndax Pharmaceuticals (Germany) Buy Hold or Sell Recommendation
| 1T3 Stock | EUR 12.80 0.10 0.78% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Syndax Pharmaceuticals is 'Sell'. Macroaxis provides Syndax Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding 1T3 positions.
Check out Syndax Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Syndax and provide practical buy, sell, or hold advice based on investors' constraints. Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Syndax |
Execute Syndax Pharmaceuticals Buy or Sell Advice
The Syndax recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Syndax Pharmaceuticals. Macroaxis does not own or have any residual interests in Syndax Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Syndax Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Syndax Pharmaceuticals Trading Alerts and Improvement Suggestions
| Syndax Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syndax Pharmaceuticals has high historical volatility and very poor performance | |
| Over 96.0% of the company shares are owned by institutions such as pension funds |
Syndax Pharmaceuticals current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Syndax analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Syndax analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Syndax Pharmaceuticals Returns Distribution Density
The distribution of Syndax Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Syndax Pharmaceuticals' future price movements. The chart of the probability distribution of Syndax Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Syndax Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Syndax Pharmaceuticals returns is essential to provide solid investment advice for Syndax Pharmaceuticals.
| Mean Return | -0.3 | Value At Risk | -5.04 | Potential Upside | 6.47 | Standard Deviation | 4.37 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Syndax Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Syndax Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Syndax Pharmaceuticals or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Syndax Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Syndax stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.35 | |
β | Beta against Dow Jones | 0.70 | |
σ | Overall volatility | 4.41 | |
Ir | Information ratio | -0.08 |
Syndax Pharmaceuticals Volatility Alert
Syndax Pharmaceuticals exhibits very low volatility with skewness of -2.87 and kurtosis of 16.44. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Syndax Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Syndax Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Syndax Pharmaceuticals Fundamentals Vs Peers
Comparing Syndax Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Syndax Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Syndax Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Syndax Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Syndax Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Syndax Pharmaceuticals to competition |
| Fundamentals | Syndax Pharmaceuticals | Peer Average |
| Return On Equity | -0.0519 | -0.31 |
| Return On Asset | -0.0292 | -0.14 |
| Profit Margin | (0.11) % | (1.27) % |
| Operating Margin | (0.11) % | (5.51) % |
| Current Valuation | 979.72 M | 16.62 B |
| Shares Outstanding | 68.1 M | 571.82 M |
| Shares Owned By Insiders | 4.22 % | 10.09 % |
| Shares Owned By Institutions | 95.78 % | 39.21 % |
| Price To Book | 4.08 X | 9.51 X |
| Price To Sales | 12.70 X | 11.42 X |
| Revenue | 139.71 M | 9.43 B |
| Gross Profit | 139.71 M | 27.38 B |
| EBITDA | 26.22 M | 3.9 B |
| Net Income | 24.93 M | 570.98 M |
| Cash And Equivalents | 95.37 M | 2.7 B |
| Cash Per Share | 3.52 X | 5.01 X |
| Total Debt | 19.89 M | 5.32 B |
| Debt To Equity | 1.90 % | 48.70 % |
| Current Ratio | 6.24 X | 2.16 X |
| Book Value Per Share | 5.62 X | 1.93 K |
| Cash Flow From Operations | 29.13 M | 971.22 M |
| Target Price | 27.67 | |
| Number Of Employees | 59 | 18.84 K |
| Beta | 1.06 | -0.15 |
| Market Capitalization | 1.67 B | 19.03 B |
| Total Asset | 449.66 M | 29.47 B |
| Z Score | 49.8 | 8.72 |
| Net Asset | 449.66 M |
Syndax Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Syndax . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 12.8 | |||
| Day Typical Price | 12.8 | |||
| Price Action Indicator | (0.05) | |||
| Period Momentum Indicator | (0.10) |
About Syndax Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Syndax Pharmaceuticals? Buying financial instruments such as Syndax Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Syndax Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Funds Thematic Idea Now
Precious Metals Funds
Funds or Etfs that invest in entities that are involved in mining, processing or dealing of precious metals. The Precious Metals Funds theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Syndax Stock
When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock:Check out Syndax Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.